# Preoperative mFOLFIRINOX (or Gem-Nab-P) +/- Isotoxic High-dose SBRT for Borderline Resectable Pancreatic Adenocarcinoma

> **NCT05083247** · PHASE2 · RECRUITING · sponsor: **Erasme University Hospital** · enrollment: 256 (estimated)

## Conditions studied

- Pancreatic Neoplasm
- Pancreatic Adenocarcinoma
- Borderline Resectable Pancreatic Adenocarcinoma

## Interventions

- **DRUG:** mFOLFIRINOX or Gemcitabine nab-paclitaxel
- **RADIATION:** Isotoxic High-Dose (iHD)-SBRT
- **PROCEDURE:** Surgery

## Key facts

- **NCT ID:** NCT05083247
- **Lead sponsor:** Erasme University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-03-24
- **Primary completion:** 2027-12-31
- **Final completion:** 2030-12-31
- **Target enrollment:** 256 (ESTIMATED)
- **Last updated:** 2023-05-23

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05083247

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05083247, "Preoperative mFOLFIRINOX (or Gem-Nab-P) +/- Isotoxic High-dose SBRT for Borderline Resectable Pancreatic Adenocarcinoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05083247. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*